The ribonuclease l-dependent antiviral roles of human 2′,5′- oligoadenylate synthetase family members against hepatitis C virus

FEBS Letters

Volumn 587, Issue 2, 2013, Pages 156-164

  Kwon, Young Chan ^a   Kang, Ju Il ^a   Hwang, Soon B ^b   Ahn, Byung Yoon ^a  

^a Korea University   (South Korea)

^b Hallym University   (South Korea)

Author keywords

2 ,5 Oligoadenylate synthetase; Antiviral protein; Hepatitis C virus; RNase L

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; 2',5' OLIGOADENYLATE SYNTHETASE 1; 2',5' OLIGOADENYLATE SYNTHETASE 3; ISOENZYME; NUCLEOTIDYLTRANSFERASE; RIBONUCLEASE L; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA DEGRADATION; RNA INTERFERENCE; TRANSIENT EXPRESSION; VIRUS REPLICATION;

2',5'-OLIGOADENYLATE SYNTHETASE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ENDORIBONUCLEASES; HEPACIVIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; LIVER NEOPLASMS; RNA INTERFERENCE; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84872109295     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2012.11.010     Document Type: Article

References (31)

1. A. Chakrabarti, B.K. Jha, and R.H. Silverman New insights into the role of RNase L in innate immunity J. Interferon Cytokine Res. 31 2011 49 57
2. K. Malathi, B. Dong, M. Gale Jr., and R.H. Silverman Small self-RNA generated by RNase L amplifies antiviral innate immunity Nature 448 2007 816 819
3. A.G. Hovanessian, and J. Justesen The human 2′-5′ oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2′-5′ instead of 3′-5′ phosphodiester bond formation Biochimie 89 2007 779 788
4. D. Moradpour, F. Penin, and C.M. Rice Replication of hepatitis C virus Nat. Rev. Microbio. 5 2007 453 463
5. Pawlotsky, J.M. (2012) New antiviral agents for hepatitis C. F1000 Biology Reports 4, 5.
6. K. Malathi, T. Saito, N. Crochet, D.J. Barton, M. Gale Jr., and R.H. Silverman RNase L releases a small RNA from HCV RNA that refolds into a potent PAMP RNA 16 2010 2108 2119
7. A.I. Su, J.P. Pezacki, L. Wodicka, A.D. Brideau, L. Supekova, R. Thimme, S. Wieland, J. Bukh, R.H. Purcell, P.G. Schultz, and F.V. Chisari Genomic analysis of the host response to hepatitis C virus infection Proc. Natl. Acad. Sci. USA 99 2002 15669 15674
8. K.J. Helbig, D.T. Lau, L. Semendric, H.A. Harley, and M.R. Beard Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector Hepatology 42 2005 702 710
9. K.I. Kim, S.R. Kim, N. Sasase, M. Taniguchi, S. Harada, K. Kinoshita, S.H. Kim, Y. Akimoto, M. Shikata, N. Kimura, S. Izawa, A. Ohtani, K. Nakao, M. Motojima, M. Kinoshita, M. Hirai, M. Ohzu, T. Hirooka, S. Nabeshima, F. Ishii, K. Tanaka, and H. Hotta 2′-,5′-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C J. Clin. Pharm. Ther. 31 2006 441 446
10. M. Shindo, K. Hamada, T. Morikawa, Y. Harano, T. Nakajima, and T. Okuno In vivo interferon system assessed by 2′-5′ oligoadenylate synthetase activity in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin Hepatol. Res. 38 2008 1213 1220
11. J.Q. Han, G. Wroblewski, Z. Xu, R.H. Silverman, and D.J. Barton Sensitivity of hepatitis C virus RNA to the antiviral enzyme ribonuclease L is determined by a subset of efficient cleavage sites J. Interferon Cytokine Res. 24 2004 664 676
12. P. Metz, E. Dazert, A. Ruggieri, J. Mazur, L. Kaderali, A. Kaul, U. Zeuge, M. Trippler, V. Lohmann, M. Binder, M. Frese, and R. Bartenschlager Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication Hepatology 2012 10.1002/hep. 25908
13. T. Wakita, T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H.G. Krausslich, M. Mizokami, R. Bartenschlager, and T.J. Liang Production of infectious hepatitis C virus in tissue culture from a cloned viral genome Nat. Med. 11 2005 791 796
14. B.D. Lindenbach, M.J. Evans, A.J. Syder, B. Wolk, T.L. Tellinghuisen, C.C. Liu, T. Maruyama, R.O. Hynes, D.R. Burton, J.A. McKeating, and C.M. Rice Complete replication of hepatitis C virus in cell culture Science 309 2005 623 626
15. J.I. Kang, S.N. Kwon, S.H. Park, Y.K. Kim, S.Y. Choi, J.P. Kim, and B.Y. Ahn PKR protein kinase is activated by hepatitis C virus and inhibits viral replication through translational control Virus Res. 142 2009 51 56
16. J.I. Kang, Y.C. Kwon, and B.Y. Ahn Modulation of the type I interferon pathways by culture-adaptive hepatitis C virus core mutants FEBS Lett. 586 2012 1272 1278
17. M.S. Park, A. Garcia-Sastre, J.F. Cros, C.F. Basler, and P. Palese Newcastle disease virus V protein is a determinant of host range restriction J. Virol. 77 2003 9522 9532
18. T. Kato, T. Date, M. Miyamoto, A. Furusaka, K. Tokushige, M. Mizokami, and T. Wakita Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon Gastroenterology 125 2003 1808 1817
19. P. Targett-Adams, and J. McLauchlan Development and characterization of a transient-replication assay for the genotype 2a hepatitis C virus subgenomic replicon J. Gen. Viol. 86 2005 3075 3080
20. D.H. Wreschner, T.C. James, R.H. Silverman, and I.M. Kerr Ribosomal RNA cleavage, nuclease activation and 2-5A(ppp(A2′p)nA) in interferon-treated cells Nucleic Acids Res. 9 1981 1571 1581
21. A. Zhou, R.J. Molinaro, K. Malathi, and R.H. Silverman Mapping of the human RNASEL promoter and expression in cancer and normal cells J. Interferon Cytokine Res. 25 2005 595 603
22. A. Zhou, J.M. Paranjape, B.A. Hassel, H. Nie, S. Shah, B. Galinski, and R.H. Silverman Impact of RNase L overexpression on viral and cellular growth and death J. Interferon Cytokine Res. 18 1998 953 961
23. B. Dong, M. Niwa, P. Walter, and R.H. Silverman Basis for regulated RNA cleavage by functional analysis of RNase L and Ire1p RNA 7 2001 361 373
24. Y. Xiang, Z. Wang, J. Murakami, S. Plummer, E.A. Klein, J.D. Carpten, J.M. Trent, W.B. Isaacs, G. Casey, and R.H. Silverman Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2′,5′-oligoadenylates Cancer Res. 63 2003 6795 6801
25. H. Kristiansen, H.H. Gad, S. Eskildsen-Larsen, P. Despres, and R. Hartmann The oligoadenylate synthetase family: an ancient protein family with multiple antiviral activities J. Interferon Cytokine Res. 31 2011 41 47
26. V. Bonnevie-Nielsen, L.L. Field, S. Lu, D.J. Zheng, M. Li, P.M. Martensen, T.B. Nielsen, H. Beck-Nielsen, Y.L. Lau, and F. Pociot Variation in antiviral 2′,5′-oligoadenylate synthetase (2'5'AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene Am J. Hum. Genet. 76 2005 623 633
27. M.K. El Awady, M.A. Anany, G. Esmat, N. Zayed, A.A. Tabll, A. Helmy, A.R. El Zayady, M.S. Abdalla, H.M. Sharada, M. El Raziky, W. El Akel, S. Abdalla, and N.G. Bader El Din Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy J. Gastroenterol. Hepatol. 26 2011 843 850
28. J.K. Lim, A. Lisco, D.H. McDermott, L. Huynh, J.M. Ward, B. Johnson, H. Johnson, J. Pape, G.A. Foster, D. Krysztof, D. Follmann, S.L. Stramer, L.B. Margolis, and P.M. Murphy Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man PLoS pathog. 5 2009 e1000321
29. I. Marie, J. Blanco, D. Rebouillat, and A.G. Hovanessian 69-kDa and 100-kDa isoforms of interferon-induced (2′-5′)oligoadenylate synthetase exhibit differential catalytic parameters Eur. J. Biochem. 248 1997 558 566
30. R.J. Lin, H.P. Yu, B.L. Chang, W.C. Tang, C.L. Liao, and Y.L. Lin Distinct antiviral roles for human 2′,5′-oligoadenylate synthetase family members against dengue virus infection J. Immunol. 183 2009 8035 8043
31. M. Kulka, M.S. Calvo, D.T. Ngo, S.Q. Wales, and B.B. Goswami Activation of the 2-5OAS/RNase L pathway in CVB1 or HAV/18f infected FRhK-4 cells does not require induction of OAS1 or OAS2 expression Virology 388 2009 169 184